Protein Aggregation, book provides valuable insights into the factors driving protein aggregation, the impact on cellular function, and the role in various diseases, offering a comprehensive overview for researchers and professionals in the field of biomedicine and biochemistry.
1. Accurate coarse grained models for protein association and
recognition
Agustí Emperador
2. In silico algorithms and computational methods to predict protein
aggregation
George Priya Doss Priya Doss C
3. Deciphering Protein Aggregation: Insights into Morphology, Contributing
Factors, and Diseases
Dileep Francis
4. Protein Aggregation in Cancer Disease
Selvaraj Chandrabose Sr.
5. Tau protein aggregation: A therapeutic target for neurodegenerative
disease
Vijay Kumar Prajapati
6. Lipids modulates Tau protein aggregation
Subashchandrabose Chinnathambi and Sreeramkumar Selvakumar
7. Heat shock proteins regulates Tau protein aggregation in AD
Subashchandrabose Chinnathambi
8. Alpha-synuclein aggregation in Parkinson disease
Edeildo Ferreira da Silva-Júnior
9. Understanding the impact of mutations on the structural stability and
conformational landscape of LDB3 gene leading to protein aggregation
myopathy: A high-performance Molecular Dynamics Simulation Study
George Priya Doss Priya Doss C
10. Role of protein aggregates in bacteria
Ewa Laskowska, Karolina Stojowska-Swdrzyska and Dorota Kuczyska-Winik
11. Molecular dynamics simulation directed the rational design of inhibitors
for aggregation inhibition of SOD1 mutants related to amyotrophic lateral
sclerosis (ALS)
George Priya Doss Priya Doss C
12. Identification of New Non-Toxic Inhibitors of Insulin Fibril Formation
and Preservatives for Insulin Preparations
Oxana V. Galzitskaya, Sergei Grishin and Alexey Surin
13. Exploring therapeutic strategies based on chaperone-mediated
disaggregation
Edeildo Ferreira da Silva-Júnior
14. The Dual Facets of p53 and Its Paralogs: Aggregation and Phase Separation
in Cancer Biology
Jerson L. Silva
15. TBC
Ferdinando Fiumara
16. Protein aggregation in health and disease: a looking glass of two faces
Guilherme A. P. de Oliveira, Jerson L. Silva, Mayra Marques, Dinarte
Moreira-Ferreira, Michelle Mota and Guilherme de Andrade
17. The aggregation propensity of Amyloid beta and Tau in Alzheimer's
disease
Subashchandrabose Chinnathambi, Murugappan Kumurappan, Madhura Chandrashekar
and Sneha Malik
18. The cross-talk between ApoE and Tau protein in Alzheimer's disease
Subashchandrabose Chinnathambi, Madhura Chandrashekar and Murugappan
Kumurappan
19. Tau PET Probes for Alzheimer's Disease detection and their structural
characterization
Subashchandrabose Chinnathambi, Sneha Malik and Madhura Chandrashekar
20. Modifiable Chemical Risk Factors for Tau protein in Alzheimer's Disease
Subashchandrabose Chinnathambi, Sneha Malik, Murugappan Kumurappan and
Madhura Chandrashekar
21. Small molecule mediated therapeutic approaches to target Alzheimer's
Disease
Subashchandrabose Chinnathambi
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
